149692-82-0

Usage

Uses

Used in Pharmaceutical Research and Development:
3-PIPERIDIN-4-YL-1H-PYRROLO[2,3-6]PYRIDINE HCL is used as a building block for the synthesis of various pharmaceutical compounds due to its unique chemical structure and properties.
Used in the Treatment of Cancer:
3-PIPERIDIN-4-YL-1H-PYRROLO[2,3-6]PYRIDINE HCL is used as a potential therapeutic agent for the treatment of various types of cancer, given its pharmacological properties and ongoing research into its efficacy.
Used in the Treatment of Neurological Disorders:
3-PIPERIDIN-4-YL-1H-PYRROLO[2,3-6]PYRIDINE HCL is used as a potential therapeutic agent for the treatment of neurological disorders, as it is being studied for its potential to address such conditions.
Used in Aqueous Solutions for Improved Solubility and Stability:
The hydrochloride (HCL) salt form of 3-PIPERIDIN-4-YL-1H-PYRROLO[2,3-6]PYRIDINE is used for its improved solubility and stability in aqueous solutions, which is beneficial for pharmaceutical formulations and drug delivery systems.

InChI:InChI=1/C12H15N3/c1-2-10-11(8-15-12(10)14-5-1)9-3-6-13-7-4-9/h1-2,5,8-9,13H,3-4,6-7H2,(H,14,15)

Upstream product

• 281658-42-2 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 612097-74-2 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-piperidine-1-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS

The present invention is directed to novel 3-piperidin-4-yl-indole derivatives of formula (I) and forms thereof, wherein X, R1, R2, R3, R4 and R5 are as herein defined, pharmaceutical compositions thereof and use as ORL-1 receptor modulators for treating, preventing or ameliorating ORL-1 receptor mediated disorders and conditions.

Pyrazole-based cathepsin S inhibitors with improved cellular potency

High potency pyrazole-based noncovalent inhibitors of human cathepsin S (CatS) were developed by modification of the benzo-fused 5-membered ring heterocycles found in earlier series of CatS inhibitors. Although substitutions on this heterocyclic framework

3-SUBSTITUTED 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF

The invention relates to 3,4-dihydro-thieno[2,3-d]pyrimidinde-4-one-derivatives which are substituted at 3-position with 5-membered heteroaryl which can be condensed with an aryl or heteroaryl radical. The heteroaryl and, optionally, the condensed aryl or heteroaryl radical 1,2 or 3 can independently include selected substitutents from C1-5-alkyl, C1-5-alkoxy, C1-5-alkylthio, halogen, CN, halogen-C1-5-alkyl, halogen-C1-5alkoxy, hydroxy, -NH2, -N(R6)2, -NH(R6), aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl, the substituents aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl 1,2 or 3 independently include selected substituents from C1-5-alkythio, halogen, CN, halogen-C1-5-alkyl, halogen-C1-5alkoxy, hydroxy, -NH2, -N(R6)2 and -NH(R6). The invention also relates to the production and use of said derivatives, especially for therapeutical purposes, e.g. in the treatment of depression.

AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS

This invention is directed to new potent and selective antagonists of H1 histamine receptors having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.